RADICAVA ORS® recognized as a MAJOR CONTRIBUTION TO PATIENT CARE by the FDA.1 Request a rep visit.
Learn about patient considerations when prescribing, dosing schedules, & administering RADICAVA ORS® (edaravone).
 | RADICAVA ORS® is recognized by the FDA as a major contribution to patient care1 |
Flexible options for administration either orally or via PEG/NG tube.2
5 mL dose administered in minutes, not hours
Portable—patients can take it at home or on the goa (see footnote)
28-day treatment cycles
(see dosing schedule below)
RADICAVA ORS® (edaravone) contains sorbitol, an ingredient with a mildly sweet taste2,3
No water or reconstitution needed
(shaking required)
Patient to store at room temperature between 20°C-25°C (68°F-77°F)a (see footnote)
RADICAVA ORS® is recognized by the FDA as a major contribution to patient care because it offers an oral route of administration that is a less burdensome option vs intravenous administration1
LEARN MORE
RADICAVA ORS® should be administered using the provided 5 mL syringe. A household teaspoon is not an adequate measuring device.2
Not actual size.
Not actual size.
Patients may be switched from 60 mg RADICAVA® intravenous infusion to 105 mg (5 mL) RADICAVA ORS® using the same dosing frequency.2
Watch a brief video that explains how patients take RADICAVA ORS® oral treatment.
FDA-approved and indicated for the treatment of ALS
May be received with riluzole
No known drug interactionsb (see footnote)
(see full Prescribing Information)
Use the Benefit Investigation and Submission Form (BIF) to start patients on treatment.
aIn the pharmacy, store RADICAVA ORS® refrigerated between 2°C-8°C (36°F-46°F) and protect from light. Do not freeze. Store upright. Patients should store RADICAVA ORS® upright at room temperature between 20°C-25°C (68°F-77°F) and protect from light. Discard 15 days after opening bottle or, if unopened, 30 days from date of shipment indicated on the carton pharmacy label.1 Return to content
bBased on in vitro drug interaction studies. Return to content
NG=nasogastric; PEG=percutaneous endoscopic gastrostomy.
References: 1. US Food and Drug Administration. Clinical superiority findings. Accessed April 11, 2024. https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinicalsuperiority-findings 2. RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022. 3. National Center for Biotechnology Information. PubChem compound summary for CID 5780, sorbitol. Accessed November 8, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/Sorbitol.
RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%)reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA ORS® (edaravone) is indicated for the treatmentof amyotrophic lateralsclerosis (ALS).
Please see full Prescribing Information also available www.radicavaors.com.
RADICAVA ORS® (edaravone) is contraindicated in patients with a history of hypersensitivity to edaravone or any of the inactive ingredients of this product. Hypersensitivity reactions (redness, wheals, and erythema multiforme) and cases of anaphylaxis (urticaria, decreased blood pressure, and dyspnea) have occurred.
Patients should be monitored carefully for hypersensitivity reactions. If hypersensitivity reactions occur, discontinue RADICAVA ORS, treat per standard of care, and monitor until the condition resolves.
RADICAVA ORS contains sodium bisulfite, a sulfite that may cause allergic-type reactions, including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown but occurs more frequently in asthmatic people.
The most common adverse reactions (≥10%)reported in RADICAVA® (edaravone)-treated patients and at least 2% more frequently than placebo were contusion (15% vs 9%), gait disturbance (13% vs 9%), and headache (10% vs 6%), respectively. In an open label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS.
Based on animal data, RADICAVA ORS may cause fetal harm.
To report suspected adverse reactions or product complaints, contact Mitsubishi Tanabe Pharma America, Inc., at 1-888-292-0058. You may also report suspected adverse reactions to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
RADICAVA ORS® (edaravone) is indicated for the treatmentof amyotrophic lateralsclerosis (ALS).
Please see full Prescribing Information also available www.radicavaors.com.
RADICAVA, RADICAVA ORS, the RADICAVA ORS logo, and the corporate symbol of Mitsubishi Tanabe Pharma America are registered trademarks of Mitsubishi Tanabe Pharma Corporation.
JourneyMate Support Program is a trademark of Mitsubishi Tanabe Pharma America, Inc.
All other company names, product names, trade/service marks or other trade names are the property of their respective owners.
For US Healthcare Professionals Only.
© 2024 Mitsubishi Tanabe Pharma America, Inc. All rights reserved. CP-OE-US-0981 04/25
You are leaving this website, hosted by Mitsubishi Tanabe Pharma America.
This link may take you to a website to which our Privacy Policy does not apply.
Mitsubishi Tanabe Pharma America does not control the content of third-party sites.
